{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:55:16Z","timestamp":1767146116239,"version":"build-2238731810"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ejps.2014.12.018","type":"journal-article","created":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T11:03:28Z","timestamp":1420283008000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Is oral absorption of vigabatrin carrier-mediated?"],"prefix":"10.1016","volume":"69","author":[{"given":"M.K.","family":"N\u00f8hr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.V.","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.I.","family":"Thale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kreilgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.U.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2014.12.018_b0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjp.0706557","article-title":"Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1","volume":"147","author":"Abbot","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0010","unstructured":"Beal, S., Sheiner, L.B., Boeckmann, A., Bauer, R.J., 2009. NONMEM User\u2019s Guides (1989\u20132009). Ellicott City, MD, USA."},{"key":"10.1016\/j.ejps.2014.12.018_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/0968768031000100759","article-title":"Substrate recognition by the mammalian proton-dependent amino acid transporter PAT1","volume":"20","author":"Boll","year":"2003","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.ejps.2014.12.018_b0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1476-5381.2012.02030.x","article-title":"Function and expression of the proton-coupled amino acid transporter Slc36a1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol","volume":"167","author":"Broberg","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1440-1746.1994.tb01560.x","article-title":"Stereospecific effects of tryptophan on gastric emptying and hunger in humans","volume":"9","author":"Carney","year":"1994","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2014.12.018_b0030","unstructured":"Drug information online, 2013. Vigabatrin Dosage. U.S. Food and Drug Administration. <http:\/\/www.drugs.com\/dosage\/vigabatrin.html>."},{"key":"10.1016\/j.ejps.2014.12.018_b0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0090-9556(25)07404-5","article-title":"Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers","volume":"21","author":"Durham","year":"1993","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.ejps.2014.12.018_b0040","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/BJ20041519","article-title":"Kinetics of bidirectional H+ and substrate transport by the proton-dependent amino acid symporter PAT1","volume":"386","author":"Foltz","year":"2005","journal-title":"Biochem. J"},{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2014.12.018_b0050","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1111\/j.1365-2125.1989.tb03457.x","article-title":"Effect of food on the absorption of vigabatrin","volume":"27","author":"Frisk-Holmberg","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0055","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1476-5381.2009.00620.x","article-title":"Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1)","volume":"159","author":"Frolund","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0060","first-page":"S1","article-title":"A full model estimation approach for covariate effects: inference based clinical importance and estimation precision","volume":"6","author":"Gastonguay","year":"2004","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2014.12.018_b0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/019262339001800201","article-title":"Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor","volume":"18","author":"Gibson","year":"1990","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejps.2014.12.018_b0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1986.227","article-title":"Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer","volume":"40","author":"Haegele","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2014.12.018_b0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.2042-7158.1995.tb05807.x","article-title":"Determination of octanol\u2013water partition coefficients by an HPLC method for anticonvulsant structure-activity studies","volume":"47","author":"Henczi","year":"1995","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/j.1552-4604.1993.tb04688.x","article-title":"Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers","volume":"33","author":"Hoke","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0085","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s11095-012-0673-0","article-title":"Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats","volume":"29","author":"Holm","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.12.018_b0090","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/0091270011430504","article-title":"Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment","volume":"52","author":"Ingwersen","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and Simulation Workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT. Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0100","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1248\/bpb.33.1117","article-title":"Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells","volume":"33","author":"Kim","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2014.12.018_b0105","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/j.1476-5381.2009.00253.x","article-title":"Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of l-tryptophan","volume":"157","author":"Larsen","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN) \u2013 a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejps.2014.12.018_b0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1124\/jpet.103.059014","article-title":"Transport of pharmacologically active proline derivatives by the human proton-coupled amino acid transporter hPAT1","volume":"309","author":"Metzner","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2014.12.018_b0120","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1096\/fj.05-3683com","article-title":"Serotonin, l-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1","volume":"19","author":"Metzner","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2014.12.018_b0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00726-005-0314-6","article-title":"Substrate specificity of the amino acid transporter PAT1","volume":"31","author":"Metzner","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejps.2014.12.018_b0130","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT. Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2013.08.034","article-title":"The absorptive flux of the anti-epileptic drug substance vigabatrin is carrier-mediated across Caco-2 cell monolayers","volume":"51","author":"N\u00f8hr","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.12.018_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2014.03.004","article-title":"Intestinal absorption of the antiepileptic drug substance vigabatrin in G\u00f6ttingen mini-pigs is unaffected by co-administration of amino acids","volume":"466","author":"N\u00f8hr","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2014.12.018_b0145","article-title":"Intestinal absorption of the antiepileptic drug substance vigabatrin is altered by infant formula in vitro and in vivo","volume":"2","author":"N\u00f8hr","year":"2014","journal-title":"Pharm. Res. Per."},{"key":"10.1016\/j.ejps.2014.12.018_b0150","first-page":"41","article-title":"Influence of amino acids on gastric emptying in young pigs","volume":"48","author":"Ochia","year":"1976","journal-title":"Acta Physiol. Acad. Sci Hung."},{"key":"10.1016\/j.ejps.2014.12.018_b0155","unstructured":"R Core Team, 2014. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <http:\/\/www.R-project.org>."},{"key":"10.1016\/j.ejps.2014.12.018_b0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.2009.03520.x","article-title":"Population pharmacokinetic analysis of varenicline in adult smokers","volume":"68","author":"Ravva","year":"2009","journal-title":"Br. J Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00003088-199223040-00003","article-title":"Vigabatrin. Clinical pharmacokinetics","volume":"23","author":"Rey","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2014.12.018_b0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-8760(86)90051-6","article-title":"Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor","volume":"4","author":"Saletu","year":"1986","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.ejps.2014.12.018_b0175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2014.12.018_b0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0016-5085(19)32408-4","article-title":"Effects of essential and nonessential amino acids on gastric emptying in the dog","volume":"69","author":"Stephens","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2014.12.018_b0185","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/mp300469m","article-title":"Dynamic analysis of fluid distribution in the gastrointestinal tract in rats: positron emission tomography imaging after oral administration of nonabsorbable marker, [(18)F]Deoxyfluoropoly(ethylene glycol)","volume":"10","author":"Takashima","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.12.018_b0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0014-5793(93)80378-8","article-title":"H(+)-coupled (Na(+)-independent) proline transport in human intestinal (Caco-2) epithelial cell monolayers","volume":"333","author":"Thwaites","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejps.2014.12.018_b0195","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis","volume":"4","author":"Wahlby","year":"2002","journal-title":"AAPS PharmSci."},{"key":"10.1016\/j.ejps.2014.12.018_b0200","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1991.tb03990.x","article-title":"Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis","volume":"32","author":"Waller","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.12.018_b0205","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"updated-by":[{"DOI":"10.1016\/j.ejps.2021.105927","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871400476X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871400476X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:41:45Z","timestamp":1747330905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809871400476X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":41,"alternative-id":["S092809871400476X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2014.12.018","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is oral absorption of vigabatrin carrier-mediated?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2014.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}